Who are the peers of the Adeshwar Meditex?

Adeshwar Meditex's peers include Tejnaksh Health, GKB Ophthalmics, Transgene Biotek, Shree Pacetronix, and Family Care, among others. The company has below-average management risk and growth, with a 1-year return of -30.77%, slightly worse than GKB Ophthalmics.

Peers: The peers of Adeshwar Meditex are Tejnaksh Health., GKB Ophthalmics, Transgene Biotek, Shree Pacetronix, Samsrita Labs, Chennai Meena, Family Care, Vanta Bioscience, and Gian Lifecare.<BR><BR>Quality Snapshot: Below Average management risk is observed at Tejnaksh Health., GKB Ophthalmics, Adeshwar Meditex, and Gian Lifecare, while Average management risk is found at Family Care. Good management risk is noted at Shree Pacetronix and Sunrest Lifescie. Below Average growth is seen at Tejnaksh Health., GKB Ophthalmics, Adeshwar Meditex, and Shree Pacetronix, while Good growth is present at Family Care. The Capital Structure is Excellent at Family Care, Good at Tejnaksh Health., GKB Ophthalmics, Shree Pacetronix, and Gian Lifecare, and Below Average at Adeshwar Meditex.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Transgene Biotek at -49.45%, while the lowest is GKB Ophthalmics at -30.67%. Adeshwar Meditex's 1-year return is -30.77%, which is slightly lower than GKB Ophthalmics. Additionally, several peers, including Tejnaksh Health., GKB Ophthalmics, Shree Pacetronix, Family Care, Gian Lifecare, and others, have negative six-month returns.

Who are in the management team of Adeshwar Meditex?

As of March 2021, the management team of Adeshwar Meditex includes Ashalata Raut and Krishnojirao Nagaraja Rao as Whole-time Directors, Sucheta Talati and Shailesh Vinayak Rajpure as Directors, and Shivani Shivshankar Tiwari as Company Secretary. Each member contributes to the company's governance and operations.

As of March 2021, the management team of Adeshwar Meditex includes the following individuals:<BR><BR>1. Ashalata Raut - Whole-time Director<BR>2. Krishnojirao Nagaraja Rao - Whole-time Director<BR>3. Sucheta Talati - Director<BR>4. Shivani Shivshankar Tiwari - Company Secretary<BR>5. Shailesh Vinayak Rajpure - Director<BR><BR>Each member plays a crucial role in the company's governance and operations.

What does Adeshwar Meditex do?

Adeshwar Meditex Ltd is a micro-cap company that manufactures and exports sterile surgical wound dressings and medical disposables. It was incorporated in 2007 and became a public company in 2021, with a market cap of INR 26 Cr.

Overview: <BR>Adeshwar Meditex Ltd is a leading manufacturer and exporter of sterile surgical wound dressings and medical disposables, operating within the healthcare services industry and classified as a micro-cap company.<BR><BR>History: <BR>Adeshwar Meditex Limited was incorporated as 'Adeshwar Meditex Private Limited' in 2007 and converted to a public limited company on March 09, 2021. There is no recent sales and profit data reported.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 26 Cr (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: 13.00 <BR>Industry P/E: N/A <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.36 <BR>Return on Equity: 5.93% <BR>Price-to-Book: 0.74 <BR><BR>Contact Details: <BR>No Company Details Available <BR>Registrar Address: Not available.

Who are the top shareholders of the Adeshwar Meditex?

The top shareholders of Adeshwar Meditex include Abhinandan N with 29.83%, Ashalata B Raut at 6.11%, and individual investors collectively owning 36.96%. There are no mutual funds or foreign institutional investors holding shares in the company.

The top shareholders of Adeshwar Meditex include the promoters, with Abhinandan N holding the largest share at 29.83%. The highest public shareholder is Ashalata B Raut, who holds 6.11%. Additionally, individual investors collectively own 36.96% of the company's shares. There are currently no mutual funds or foreign institutional investors holding shares in the company.

How big is Adeshwar Meditex?

As of 23rd July, Adeshwar Meditex Ltd has a market capitalization of 26.00 Cr, classifying it as a Micro Cap company, with Shareholder's Funds of 34.91 Cr and Total Assets of 63.90 Cr; however, there is no valid financial data available for Net Sales or Net Profit for the latest four quarters.

As of 23rd July, <BR><BR>Market Cap: Adeshwar Meditex Ltd has a market capitalization of 26.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales or Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2024, with Shareholder's Funds amounting to 34.91 Cr and Total Assets totaling 63.90 Cr.

When is the next results date for Adeshwar Meditex?

The next results date for Adeshwar Meditex is 12 November 2025.

The next results date for Adeshwar Meditex is scheduled for 12 November 2025.

How has been the historical performance of Adeshwar Meditex?

Adeshwar Meditex reported a net profit of 0.79 crore and net sales of 64.76 crore for the year ending March 2022, with an operating profit margin of 5.2%. Total liabilities and assets were both 72.45 crore, and the book value per share increased to 21.45.

Answer:<BR>The historical performance of Adeshwar Meditex shows a consolidated net profit of 0.79 crore for the year ending March 2022, with net sales recorded at 64.76 crore. The total operating income for the same period was also 64.76 crore, while total expenditure, excluding depreciation, amounted to 61.39 crore, resulting in an operating profit (PBDIT) of 3.60 crore. The profit before tax was 1.19 crore, leading to a profit after tax of 0.79 crore. The earnings per share (EPS) stood at 0.55, with a diluted EPS of 0.59. The operating profit margin was 5.2%, and the profit after tax margin was 1.22%. <BR><BR>In terms of balance sheet performance, the total liabilities as of March 2022 were 72.45 crore, with total assets also at 72.45 crore. The company's shareholder's funds were reported at 30.95 crore. Over the years, the book value per share has shown a steady increase, reaching 21.45 by March 2022. Cash flow from operating activities was negative at -2.00 crore for the year ending March 2022, while the net cash inflow/outflow was 0.00 crore. The company has maintained a consistent share capital of 14.43 crore since March 2021, indicating stability in its equity base.

Is Adeshwar Meditex overvalued or undervalued?

As of November 13, 2025, Adeshwar Meditex is considered undervalued with a favorable outlook, featuring a PE ratio of 11.33 and an EV to EBITDA of 6.75, significantly lower than its peers, despite a year-to-date stock underperformance of -37.5% compared to the Sensex's 8.11%.

As of 13 November 2025, Adeshwar Meditex has moved from a fair to an attractive valuation grade, indicating a more favorable outlook for the company. The stock is currently considered undervalued, especially when compared to its peers. Key ratios include a PE ratio of 11.33, an EV to EBITDA of 6.75, and a Price to Book Value of 0.62, which suggest that the company is trading at a significant discount relative to its earnings and asset value.<BR><BR>In comparison to its peers, Adeshwar Meditex stands out with a much lower PE ratio than Poly Medicure, which has a PE of 55.2, and Blue Jet Health at 28.63. The EV to EBITDA ratio of 6.75 also highlights its attractiveness compared to other expensive peers like Laxmi Dental at 38.93. Despite the recent underperformance of Adeshwar Meditex's stock against the Sensex, with a YTD return of -37.5% compared to the Sensex's 8.11%, the current valuation metrics suggest that it presents a compelling investment opportunity.

Which are the latest news on Adeshwar Meditex?

Why is Adeshwar Meditex falling/rising?

As of 03-Dec, Adeshwar Meditex Ltd's stock price is stable at Rs 17.70, with a recent performance rise of 11.99% today and a significant increase in investor participation. However, it has a year-to-date decline of 31.92% and has shown erratic trading behavior.

As of 03-Dec, Adeshwar Meditex Ltd's stock price is currently stable at Rs 17.70, showing no change (0.00%). However, the stock has recently experienced a notable rise in performance, particularly today, where it outperformed its sector by 11.99% and opened with a gain of 10.63%. The stock reached an intraday high of Rs 17.70, reflecting this upward movement.<BR><BR>In terms of trading activity, there has been a significant increase in investor participation, with delivery volume rising by 650% compared to the 5-day average. This suggests a growing interest among investors, which can contribute positively to the stock's price stability or potential rise.<BR><BR>Despite these positive indicators, it is important to note that the stock has faced challenges over longer periods, with a year-to-date decline of 31.92% and a 1-year decline of 23.87%. Additionally, the stock has not traded on 4 out of the last 20 days, indicating erratic trading behavior.<BR><BR>Overall, while the stock is currently stable, the recent performance improvements and increased investor participation suggest a potential for future upward movement, despite the historical declines.